[Abstract] Many therapeutic viruses, such as oncolytic viruses, vaccines, or gene therapy vectors, may be administered by the intravenous route to maximize their delivery to target tissues. Blood components, such as antibody, complement and blood cells (such as neutrophils, monocytes, T cells, B cells or platelets) may result in viral neutralization and therefore reduce the therapeutic efficacy. This protocol will describe an in vitro assay by which to test the interaction of viruses with blood components. The effect of various factors can be isolated through fractionation. While whole blood can offer the most physiologically relevant snapshot, plasma can investigate the effects of antibody in concert with complement, and heat inactivated plasma will interrogate the effect of antibody alone.
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http://www.bio-protocol.org/e1674 Vol 5, Iss 23, Dec 05, 2015 2. Venous blood should be collected by a trained phlebotomist into the vacutainer tube using a butterfly needle with connected vacutainer holder.
3. Immediately after blood collection, using the insulin syringe, inject Refludan (70 μl of a 100x stock of Refludan to a final concentration of 50 μg/ml) through the rubber top of the tube. Invert several times (4-5 times) at room temperature to ensure proper mixing.
C. Neutralization assay 1. Prepare a 250 μl aliquot of whole blood per blood donor in an Eppendorf tube.
2. Transfer remaining blood to a 15 ml falcon tube and spin at 800 x g for 5 min at room temperature to obtain plasma. 
